Media stories about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive on Friday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.6968462476728 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several equities analysts have weighed in on the company. Needham & Company LLC cut their price target on GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Canaccord Genuity restated a “buy” rating and set a $14.00 price target on shares of GenMark Diagnostics in a report on Monday, October 30th. Raymond James Financial restated a “market perform” rating on shares of GenMark Diagnostics in a report on Friday, November 3rd. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub lowered GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $11.80.

Shares of GenMark Diagnostics (NASDAQ:GNMK) opened at $5.19 on Friday. The stock has a market capitalization of $298.08 and a P/E ratio of -4.25. GenMark Diagnostics has a one year low of $3.63 and a one year high of $13.67. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $14.56 million. GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. GenMark Diagnostics’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.27) earnings per share. sell-side analysts predict that GenMark Diagnostics will post -1.18 earnings per share for the current fiscal year.

In other news, insider Hany Massarany sold 8,252 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $4.74, for a total value of $39,114.48. Following the completion of the sale, the insider now directly owns 362,957 shares of the company’s stock, valued at approximately $1,720,416.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Kagnoff purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average cost of $4.13 per share, with a total value of $82,600.00. Following the completion of the purchase, the director now directly owns 64,413 shares in the company, valued at approximately $266,025.69. The disclosure for this purchase can be found here. Insiders sold a total of 20,126 shares of company stock valued at $96,564 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2018/02/02/genmark-diagnostics-gnmk-given-daily-media-impact-score-of-0-10.html.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.